An engineered lentivirus was created to avoid some of the drawbacks associated with current gene therapy vectors for sickle cell disease (SCD) and beta-thalassemia. Researchers reported Friday that a ...
VIRxSYS (www.virxsys.com) is developing a unique technology that is advancing both gene therapy and HIV treatment. VRX496 uses a lentiviral vector to deliver a payload to block the replication of HIV.
Merck KGaA and subsidiary MilliporeSigma are doubling down on their gene therapy bets with a hefty nine-figure investment into expanded viral vector production. MilliporeSigma will spend $110 million ...
Recent clinical holds of several studies and an FDA advisory committee meeting has put the safety of gene therapy under the spotlight. To increase the efficacy of gene therapy and reduce the risk of ...
Some of the newest and most exciting gene therapy technologies share a problem: They’re too bulky. They rely on multiple functional DNA and protein elements that must reach target cells all at the ...
Researchers at the University of Pennsylvania School of Medicine report the first clinical test of a new gene therapy based on a disabled AIDS virus carrying genetic material that inhibits HIV ...
Outside the expanded lab space at CHOP's $75 clinical manufacturing facility are, from left, Johannes C. M. van der Loo, director of the Clinical Vector Core at CHOP, Olga Zelenaia, the core's quality ...
Researchers have developed a new and improved viral vector -- a virus-based vehicle that delivers therapeutic genes -- for use in gene therapy for sickle cell disease. In advanced lab tests using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback